Generate Biomedicines (GENB) IPO: Everything You Need to Know

Generate Biomedicines (GENB) is set to debut on the Nasdaq on February 27, 2026, with an initial public offering (IPO) that aims to raise up to $425 million. The company plans to offer 25 million shares at a price range of $15 to $17 per share, which would value Generate at up to $2.2 billion. As a biotech firm leveraging cutting-edge AI in drug development, Generate Biomedicines is entering a market with increased interest in biotech IPOs, reflecting broader investor optimism for innovation in the pharmaceutical sector.

Recent developments highlight the company's strategic position in the evolving biotech landscape. Generate Biomedicines has been refining its platform to design novel protein-based medicines using machine learning and generative biology, with the goal of accelerating drug discovery and development. The company is currently working on therapies for severe asthma and COPD, with late-stage trials for asthma expected to be fully enrolled by the end of 2027 or early 2028. Early-stage results from its COPD study are anticipated in 2026, adding a near-term catalyst for investor interest.

In the past few months, Generate has secured significant partnerships and funding. Notably, it has received $110 million in payments from collaborations with Novartis and Amgen, and it raised $273 million in a Series C round in 2023. These investments were led by prominent firms such as Amgen, Nvidia’s venture capital arm, and MAPS Capital. The company’s financials, however, reflect the high costs associated with drug development, as it posted a net loss of $223 million in 2025, up from $181 million the previous year.

Generate Biomedicines has also made strides in leadership and governance. Noubar Afeyan, co-founder of Moderna and board chair, controls 57% of the company’s shares through Flagship Pioneering, while CEO Michael Nally holds 6.4%. The IPO is being managed by a team of top-tier underwriters, including Goldman Sachs and Morgan Stanley, signaling strong institutional support.

With the IPO expected to price on February 26 and list on February 27, investors are closely watching the company’s progress. The upcoming weeks will be crucial for assessing investor demand and the company’s market reception. Given its innovative approach and key partnerships, Generate Biomedicines is positioned to capture attention in a biotech market showing signs of renewed momentum.